Abstract
Since the identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small cell lung cancers and the concomitant success of front-line EGFR inhibitors in treating cancers with these mutations, interest in identifying further significant oncogenic driver mutations or biomarkers has increased. Current mutations under consideration include BRAF, MET, RET, and HER2. This article discusses the current research into these biomarkers and the significance of biomarkers for treating NSCLC.
